Indication
Immunologic Factors
3 clinical trials
3 products
1 drug
Clinical trial
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) With or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults With Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission With Minimal Residual Disease (MRD) or Relapsed/Refractory (R/R) AMLStatus: Recruiting, Estimated PCD: 2024-06-03
Product
CYNK-001Clinical trial
A Double-blind, Randomized, Prospective, Placebo-controlled Trial to Assess the Immunogenicity, Safety, and Tolerability of a Coronavirus Vaccine in Healthy Volunteers Aged 18 to 60 YearsStatus: Completed, Estimated PCD: 2021-08-30
Product
Subunit recombinant vaccineDrug
VarlilumabClinical trial
A Phase 2, Open-label, Study to Evaluate the Safety and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV, MVA-BN-Filo in Adults and Children Originally Enrolled in the Control Arm of the EBOVAC-Salone StudyStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
Ad26.ZEBOV, MVA-BN-Filo